Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Rheumatology | 7 | 2021 | 1213 | 1.25 | Why? |
| Rheumatic Diseases | 7 | 2021 | 2675 | 0.90 | Why? |
| Allopurinol | 1 | 2018 | 59 | 0.71 | Why? |
| Pathology | 1 | 2018 | 121 | 0.62 | Why? |
| Prediabetic State | 1 | 2018 | 200 | 0.59 | Why? |
| Pathology, Clinical | 1 | 2018 | 407 | 0.52 | Why? |
| Patient Participation | 2 | 2018 | 829 | 0.50 | Why? |
| Self-Management | 1 | 2019 | 546 | 0.49 | Why? |
| Weight Loss | 1 | 2018 | 826 | 0.46 | Why? |
| Patient Education as Topic | 2 | 2019 | 1476 | 0.46 | Why? |
| Educational Measurement | 1 | 2018 | 930 | 0.41 | Why? |
| Chronic Pain | 1 | 2019 | 736 | 0.41 | Why? |
| Pain Management | 1 | 2019 | 854 | 0.41 | Why? |
| Glycated Hemoglobin A | 1 | 2018 | 1316 | 0.40 | Why? |
| Self Care | 1 | 2018 | 918 | 0.39 | Why? |
| Vascular Diseases | 1 | 2018 | 846 | 0.38 | Why? |
| Arthritis, Rheumatoid | 3 | 2021 | 2043 | 0.35 | Why? |
| Information Dissemination | 3 | 2020 | 2986 | 0.35 | Why? |
| Antirheumatic Agents | 5 | 2021 | 3023 | 0.32 | Why? |
| Education, Medical, Undergraduate | 1 | 2018 | 1392 | 0.29 | Why? |
| Internet | 3 | 2021 | 6204 | 0.29 | Why? |
| Telemedicine | 5 | 2021 | 25032 | 0.28 | Why? |
| Education, Medical | 1 | 2018 | 2461 | 0.22 | Why? |
| New Zealand | 2 | 2018 | 2073 | 0.22 | Why? |
| Consumer Health Informatics | 1 | 2021 | 57 | 0.22 | Why? |
| Wheelchairs | 1 | 2019 | 22 | 0.20 | Why? |
| Self-Evaluation Programs | 1 | 2018 | 3 | 0.19 | Why? |
| Students, Medical | 1 | 2018 | 4032 | 0.19 | Why? |
| Peer Influence | 1 | 2018 | 24 | 0.18 | Why? |
| Health Records, Personal | 1 | 2018 | 63 | 0.17 | Why? |
| Waist Circumference | 1 | 2018 | 199 | 0.17 | Why? |
| Peripheral Vascular Diseases | 1 | 2018 | 133 | 0.16 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.16 | Why? |
| Rheumatologists | 1 | 2020 | 346 | 0.16 | Why? |
| Medical Informatics | 2 | 2021 | 648 | 0.16 | Why? |
| Adiposity | 1 | 2018 | 329 | 0.14 | Why? |
| Patient Reported Outcome Measures | 1 | 2020 | 912 | 0.14 | Why? |
| Healthy Lifestyle | 1 | 2018 | 447 | 0.13 | Why? |
| Confidentiality | 1 | 2018 | 581 | 0.12 | Why? |
| Privacy | 1 | 2018 | 636 | 0.12 | Why? |
| Telephone | 1 | 2021 | 1705 | 0.12 | Why? |
| Counseling | 1 | 2018 | 747 | 0.11 | Why? |
| Social Media | 4 | 2021 | 5798 | 0.11 | Why? |
| Data Collection | 1 | 2021 | 1769 | 0.11 | Why? |
| Mass Media | 1 | 2020 | 837 | 0.11 | Why? |
| Registries | 5 | 2021 | 12327 | 0.11 | Why? |
| Glucocorticoids | 3 | 2021 | 4431 | 0.10 | Why? |
| Learning | 1 | 2018 | 1181 | 0.10 | Why? |
| Patient-Centered Care | 1 | 2018 | 860 | 0.10 | Why? |
| Attitude | 1 | 2018 | 1481 | 0.09 | Why? |
| Disabled Persons | 1 | 2019 | 1152 | 0.09 | Why? |
| Hydroxychloroquine | 3 | 2020 | 12447 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Health Literacy | 1 | 2018 | 1078 | 0.09 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.08 | Why? |
| Humans | 23 | 2021 | 930598 | 0.08 | Why? |
| Motivation | 1 | 2018 | 1640 | 0.08 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| Education, Medical, Graduate | 1 | 2020 | 2082 | 0.08 | Why? |
| Janus Kinase Inhibitors | 2 | 2020 | 682 | 0.07 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.06 | Why? |
| Patient Care Team | 1 | 2017 | 3556 | 0.06 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.06 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.06 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.06 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Biomedical Research | 1 | 2021 | 5270 | 0.05 | Why? |
| Health Behavior | 1 | 2018 | 4449 | 0.05 | Why? |
| Education, Distance | 1 | 2020 | 4956 | 0.05 | Why? |
| Primary Health Care | 1 | 2018 | 4839 | 0.05 | Why? |
| Spondylarthropathies | 1 | 2020 | 163 | 0.05 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.05 | Why? |
| Data Anonymization | 1 | 2018 | 32 | 0.05 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.04 | Why? |
| Stakeholder Participation | 1 | 2021 | 481 | 0.04 | Why? |
| Prednisone | 1 | 2020 | 652 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Bias | 1 | 2020 | 1109 | 0.04 | Why? |
| Azithromycin | 2 | 2020 | 3943 | 0.04 | Why? |
| Purines | 1 | 2020 | 816 | 0.04 | Why? |
| Azetidines | 1 | 2020 | 722 | 0.03 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.03 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.03 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.03 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Arthritis, Psoriatic | 1 | 2020 | 625 | 0.03 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.03 | Why? |
| Vasculitis | 1 | 2020 | 691 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.03 | Why? |
| Aged | 5 | 2021 | 215776 | 0.03 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.03 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.03 | Why? |
| Sulfonamides | 1 | 2020 | 1294 | 0.03 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.03 | Why? |
| Middle Aged | 5 | 2021 | 270681 | 0.03 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.03 | Why? |
| Pyrazoles | 1 | 2020 | 1791 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Adult | 4 | 2021 | 244371 | 0.02 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2020 | 1380 | 0.02 | Why? |
| Male | 5 | 2021 | 367725 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.02 | Why? |
| Female | 5 | 2021 | 380317 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2020 | 6543 | 0.02 | Why? |
| Internationality | 1 | 2021 | 3297 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Curriculum | 1 | 2020 | 3083 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.02 | Why? |
| Mobile Applications | 1 | 2021 | 3032 | 0.02 | Why? |
| Electronic Health Records | 1 | 2018 | 3492 | 0.02 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Research Design | 1 | 2020 | 5830 | 0.02 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2020 | 8041 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| United States | 1 | 2021 | 46150 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Child | 1 | 2019 | 70012 | 0.01 | Why? |
| Health Personnel | 1 | 2019 | 29646 | 0.01 | Why? |
Grainger's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(133)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(146)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_